相关实验视频
Updated: Jul 12, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
提尔泽帕提德:一种对肥胖的有希望的治疗方法?
Christine G Niedbala1, Roxanne Sprague
1Christine G. Niedbala is an assistant professor in the PA program at Springfield (Mass.) College and practices in primary care at Ludlow (Mass.) Medical Center. Roxanne Sprague is an assistant professor in the PA program at Springfield College. The authors have disclosed no potential conflicts of interest, financial or otherwise.
蒂尔泽帕提德是一种双烯类型,对肥胖患者显著减肥有前途. 这种新的治疗方法提供了一个新的选择,当传统的医疗管理不足于推的减肥目标时.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖是美国普遍存在的疾病,与较高的死亡率和医疗保健费用有关.
- 目前的指导方针建议,肥胖患者的体重减轻目标为10%.
- 肥胖现有的医疗管理策略往往证明是不够的.
研究的目的:
- 讨论蒂尔泽帕提德在控制肥胖症中的作用.
- 突出提尔泽帕提德作为减肥的新疗法选择.
主要方法:
- 作为双烯类比剂的蒂尔泽帕提德的机制的审查.
- 讨论其在诱导减肥方面的有效性.
主要成果:
- 蒂尔泽帕提德是一种双缩类型,具有显著减肥的潜力.
- 它代表了一种用于肥胖管理的新药学方法.
结论:
- 蒂尔泽帕提德为治疗肥胖提供了一个有前途的新途径.
- 它的双增蛋白作用可能有助于实现推的减肥目标.
相关概念视频
Obesity
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Antidepressant Drugs: MAOIs and Other Agents
Drugs for Treatment of Constipation-Predominant IBS

